Publications
Clinical research
Joleen M. Hubbard, Levente Molnár, József Tóth, Orsolya Lőrincz, Zsolt Csiszovszki, Eszter Somogyi, Enikő R. Tőke Evaluation of HLA genotype as predictive biomarker for immunological and clinical responses upon vaccination with PolyPEPI1018 cancer vaccine against colorectal cancer ESMO 2024 poster
Joleen M. Hubbard, Daniel H. Ahn, Jeremy C. Jones, Mojun Zhu, Kathleen L. Wittenberger, Zsolt Csiszovszki, Eszter Somogyi, Orsolya Lőrincz, Levente Molnár, József Tóth, Hagop Youssoufian, Enikő R. Tőke A Phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301) ASCO 2024 poster
Joleen M. Hubbard, Daniel H. Ahn, Jeremy Clifton Jones, Kathleen Wittenberger, Mariann Kremlitzka, Zsolt Csiszovszki, Eszter Somogyi, Orsolya Lőrincz, Levente Molnár, József Tóth, Hagop Youssoufian, Enikő R. Tőke A Phase II, multicenter, open label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite stable metastatic colorectal (MSS mCRC) cancer (Oberto 301): initial results ESMO 2023 poster
Joleen M Hubbard, Tyler Zemla, Rondell P Graham, Zhaohui Jin, Mojun Zhu, Jessica L. Mitchell, Elise Novo, Eva Vegh, Orsolya Lőrincz, Zsolt Csiszovszki, Mariann Kremlitzka, Eszter Somogyi, Levente Molnár, József Tóth, Enikő R Tőke PolyPEPI1018 vaccine in combination with TAS-102 in participants with late stage microsatellite stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO 201) ASCO 2023 poster
Joleen M Hubbard, Tyler Zemla, Rondell P. Graham, Zhaohui Jin, Mojun Zhu, Jessica L. Mitchell, Eva Vegh, Orsolya Lőrincz, Zsolt Csiszovszki, Mariann Kremlitzka, Eszter Somogyi, Levente Molnár, József Tóth , Enikő R. Tőke Phase Ib open-label study to evaluate safety, tolerability, immunogenicity and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC) (OBERTO-201) ASCO GI 2023 poster
Joleen M. Hubbard, Daniel H. Ahn, Jeremy Clifton Jones, Kathleen Wittenberger, Levente Molnar, Orsolya Lorincz, Eszter Somogyi, Zsolt Csiszovszki, Hagop Youssoufian, Eniko R. Toke Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301) ASCO GI 2023 poster
Joleen M. Hubbard, MD: Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC January 27, 2023, ASCO GI 2023 by onclive.com
Joleen M. Hubbard, Enikő R. Tőke, Roberto Moretto, Rondell P. Graham, Hagop Youssoufian, Orsolya Lőrincz, Levente Molnár, Zsolt Csiszovszki, Jessica L. Mitchell, Jaclynn Wessling, József Tóth, Chiara Cremolini Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study Clinical Cancer Research clincanres.0112.2022. (DOI: 10.1158/1078-0432.CCR-22-0112)
István Miklós, Levente Molnár, József Tóth, Orsolya Lőrincz, Zsolt Csiszovszki, Péter Páles, Katalin Pántya, Eszter Somogyi, Enikő R. Tőke Association between cancer risk and HLA genotype can be explained by anti-tumor immunity, February 2021, DOI:10.21203/rs.3.rs-244862/v1
Orsolya Lőrincz, Levente Molnár, Zsolt Csiszovszki, Eszter Somogyi, József Tóth, Kata Pántya, Péter Páles, Enikő R. Tőke Identification of frequently presented non-mutated tumor-specific immunogens for the development of both off-the-shelf and personalized vaccines without need for tumor biopsy SITC 2021 poster (narration).
Orsolya Lőrincz, József Tóth, Levente Molnár, István Miklós, Kata Pántya, Mónika Megyesi, Eszter Somogyi, Zsolt Csiszovszki, Enikő R. Tőke In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines November 2021 Cells 10(11):3048 DOI:10.3390/cells10113048
Joleen Marie Hubbard, Chiara Cremolini, Rondell P Graham, Roberto Moretto, Jessica L Mitchell, Jaclynn Wessling, Enikő R. Tőke, Zsolt Csiszovszki, Orsolya Lőrincz, Levente Molnár, Eszter Somogyi, Mónika Megyesi, Kata Pántya, József Tóth, Péter Páles, István Miklós, Alfredo Falcone Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine/bevacizumab maintenance therapy in metastatic colorectal cancer (mCRC) patients ASCO 2020 poster P4048.
Joleen M Hubbard, Chiara Cremolini, Rondell P Graham, Roberto Moretto, Jessica L. Mitchell, Jaclynn Wessling, Enikő R. Tőke, Zsolt Csiszovszki, Orsolya Lőrincz, Levente Molnár, Eszter Somogyi, Mónika Megyesi, Kata Pántya, József Tóth, Péter Páles, István Miklós, Alfredo Falcone PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC). SITC 2019 poster P329.
Zsolt Csiszovszki, Levente Molnár, Péter Páles, József Tóth, Orsolya Lőrincz, Katalin Pántya, Eszter Somogyi, Wolfgang Schönharting, Sybille Urban, Tim Röhnisch, Mónika Megyesi, Enikő R. Tőke Warehouse approach for the development of personalized cancer vaccines by using Personal Antigen Selection Calculator (PASCal) without need for tumor biopsy. SITC 2019 poster P677.
Joleen Marie Hubbard, Chiara Cremolini, Rondell P Graham, Roberto Moretto, Jessica L. Mitchell, Jaclynn Wessling, Enikő R. Tőke, Zsolt Csiszovszki, Orsolya Lőrincz, Levente Molnár, Eszter Somogyi, Mónika Megyesi, Kata Pántya, József Tóth, Péter Páles, István Miklós, Alfredo Falcone. Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker. ESMO 2019 poster #606P.
Eszter Somogyi, Zsolt Csiszovszki, Orsolya Lőrincz, József Tóth, Levente Molnár, Wolfgang Schönharting, Sybille Urban, Tim Röhnisch, Katalin Pántya, Péter Páles, Mónika Megyesi, Enikő R. Tőke. Personal Antigen Selection Calculator (PASCal) for the design of personal cancer vaccines. ESMO 2019 poster discussion #1181PD.
I. Miklos, L. Molnar, J. Toth, O. Lorincz, Z. Csiszovszki, P. Pales, K. Pántya, M. Megyesi, E. Somogyi, E. Tőke. Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations. ESMO 2019 poster #1423P.
Orsolya Lőrincz, József Tóth, Mónika Megyesi, Kata Pántya, István Miklós, Eszter Somogyi, Zsolt Csiszovszki, Péter Páles, Levente Molnár, Enikő R. Tőke. Computational model to predict response rate of clinical trials. ESMO 2019 poster #1935P.
Hubbard JM, Cremolini C, Graham RP, Moretto R, Mitchell JL, Wessling J, Tőke ER, Csiszovszki Zs, Lőrincz O, Molnár L, Somogyi E, Megyesi M, Pántya K, Tóth J, Miklós I, Lisziewicz J, Lori F, Falcone A. A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO). Journal of Clinical Oncology 37, 2019 (suppl; abstr 3557).
Tőke ER, Megyesi M, Molnár L, Tóth J, Lőrincz O, van der Burg SH, Welters M, Melief CJ, Schönharting W, Urban S, Roehnisch T, Heine U, Somogyi E, Csiszovszki Zs, Pántya K, Páles P, Miklós I, Lori F, Lisziewicz J. Prediction the clinical outcomes of cancer patients after peptide vaccination. Journal of Clinical Oncology 37, 2019 (suppl; abstr e14295).
Lőrincz O, Tőke ER, Somogyi E, Csiszovszki Zs, Megyesi M, Pántya K, Tóth J, Molnár L, Miklós I, Lori F, Lisziewicz J. Human model to predict the outcome of cancer vaccine clinical trials. Journal of Clinical Oncology 37, 2019 (suppl; abstr e14298).
Miklós I, Tőke ER, Megyesi M, Molnár L, Tóth J, Lőrincz O, Somogyi E, Csiszovszki Zs, Pántya K, Páles P, Lori F, Lisziewicz J. Determination of the immunogenetic risk of developing cancer. Journal of Clinical Oncology 37, 2019 (suppl; abstr e13132).
Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9. PubMed PMID: 22590502; PubMed Central PMCID: PMC3348904.
Animal model
Eszter Somogyi, Mariann Kremlitzka, Zsolt Csiszovszki, Levente Molnár, Orsolya Lőrincz, József Tóth, Leon de Waal, Sofie Pattijn, Wencke Reineking, Andreas Beineke and Enikő R. Tőke: T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptidevaccination, in Syrian hamsters DOI 10.3389/fimmu.2023.1111629
Eszter Somogyi, Zsolt Csiszovszki, Levente Molnár, Orsolya Lőrincz, József Tóth, Sofie Pattijn, Jana Schockaert, Aurélie Mazy, István Miklós, Katalin Pántya, Péter Páles and Enikő R. Tőke: A peptide vaccine candidate tailored to individuals’ genetics mimics the multi-targeted T cell immunity of COVID-19 convalescent subjects doi: 10.3389/fgene.2021.684152
Eszter Somogyi, Zsolt Csiszovszki, Levente Molnár, Orsolya Lőrincz, József Tóth, Sofie Pattijn, Jana Schockaert, Aurélie Mazy, István Miklós, Katalin Pántya, Péter Páles, Enikő R. Tőke: Peptide vaccine candidate mimics the heterogeneity of natural SARS-CoV-2 immunity in convalescent humans and induces broad T cell responses in mice models doi: https://doi.org/10.1101/2020.10.16.339937
Verstrepen BE, Oostermeijer H, Fagrouch Z, van Heteren M, Niphuis H, Haaksma T, Kondova I, Bogers WM, de Filette M, Sanders N, Stertman L, Magnusson S, Lőrincz O,Lisziewicz J, Barzon L, Palù G, Diamond MS, Chabierski S, Ulbert S, Verschoor EJ: Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLoS One. 2014 Nov 13;9(11):e112568. doi: 10.1371/journal.pone.0112568. PubMed PMID: 25392925.
De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lőrincz O, Sanders NN: Vaccination of mice using the West Nile virus E- protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal PLoS One, 2014, in press.
Garaczi E, Szabó K, Francziszti L, Csiszovszki Z, Lőrincz O, Tőke ER, Molnár L, Bitai T, Jánossy T, Bata-Csörgő Z, Kemény L, Lisziewicz J. DermAll nanomedicine for allergen- specific Nanomedicine. 2013 Nov;9(8):1245-54. doi: 10.1016/j.nano.2013.05.011. Epub 2013 Jun 6. PubMed PMID: 23747740.
Vaccine formulation
Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. 2013 Jan;9(1):28-38. doi: 10.1016/j.nano.2012.05.012. Epub 2012 May 30. Review. PubMed PMID: 22659241.
Lőrincz O, Tőke ER, Somogyi E, Horkay F, Chandran PL, Douglas JF, Szebeni J, Lisziewicz J. Structure and biological activity of pathogen-like synthetic Nanomedicine. 2012 May;8(4):497-506. doi:10.1016/j.nano.2011.07.013. Epub 2011 Aug 10. PubMed PMID: 21839051; PubMedCentral PMCID: PMC3274662.
Tőke ER, Lőrincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm. 2010 Jun 15;392(1-2):261-7. doi: 10.1016/j.ijpharm.2010.03.048. Epub 2010 Mar 25. PubMed PMID: 20347027.
Vaccine delivery
Kolonics A, Csiszovszki Z, Tőke ER, Lőrincz O, Haluszka D, Szipőcs R.: In vivo study of targeted nanomedicine delivery into Langerhans cells by multiphoton laser scanning microscopy. Experimental Dermatology, 2014. 23(8):596-605. PubMed PMID: 24903756.
Tőke ER, Lőrincz O, Csiszovszki Zs, Somogyi E, Felföldi G, Molnár L, Szipőcs R, Kolonics A, Malissen B, Lori F, Trocio J, Bakare N, Horkay F, Romani N, Tripp CH, Stoitzner P and Lisziewicz J: Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes. Gene Therapy, 2014. Jun;21(6):566-74. PubMed PMID: 24694539.
Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine. 2011 Jan 17;29(4):744-53. doi: 10.1016/j.vaccine.2010.11.019. Epub 2010 Nov 23. PubMed PMID: 21109034.